74455
document
Intravenous hyperimmune globulin prophylaxis against cytomegalovirus interstitial pneumonitis after allogenic bone marrow transplantation . In an attempt to reduce the incidence of lethal cytomegalovirus ( CMV ) interstitial pneumonitis after allogenic bone marrow transplantation 49 patients were randomized in a multicenter controlled study to receive either CMV-hyperimmune globulin or a control immune globulin with low anticytomegalovirus titer . Immune globulin was administered intravenously 6 times with 20 days interval , starting on day 7 before transplantation . Patients receiving CMV hyperimmune globulin or control immune globulin were comparable with regard to age , diagnosis , pretransplant anti-CMV titer , incidence of graft-versus-host disease and transfusions . In each group , the incidence of histologically proven CMV interstitial pneumonitis during the first 110 days post BMT was recorded . Six of 23 patients in the control group versus 1 of 26 in the CMV hyperimmune globulin group died of CMV interstitial pneumonitis ( p less than 0.05 ) . No significant effect on idiopathic pneumonitis or survival was observed .
74456
Intervention_Pharmacological
Intravenous hyperimmune globulin prophylaxis
74457
Intervention_Physical
allogenic bone marrow transplantation
74458
Intervention_Pharmacological
CMV-hyperimmune globulin
74459
Intervention_Control
control immune globulin with low anticytomegalovirus titer .
74460
Intervention_Pharmacological
Immune globulin
74461
Intervention_Pharmacological
CMV hyperimmune globulin
74462
Intervention_Control
control immune globulin
74463
Intervention_Control
control
74464
Intervention_Pharmacological
CMV hyperimmune globulin
74465
Outcome_Physical
cytomegalovirus ( CMV ) interstitial pneumonitis
74466
Outcome_Adverse-effects
CMV interstitial pneumonitis
74467
Outcome_Mortality
died of CMV interstitial pneumonitis
74468
Outcome_Mortality
idiopathic pneumonitis
74469
Outcome_Mortality
survival
74470
Participant_Condition
allogenic bone marrow transplantation .